Table 1 |.
Characteristics of trials
| No. of subjects | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Author (year) | Randomized | Blinded | Whites or nonblacksa |
Blacks | Mean age | Percent female |
Treatment | Duration (weeks) |
Drug | Min-max dose (mg/day) |
| Krakoff (1990)21b | No | No | 803 | 304 | 54 | 32 | Monotherapy | 13–18 | Nifedipine± | 30–180 |
| Black (1992)27c | Yes | Yes | 53a | 34 | 55 | 33 | Monotherapy | 12 | Diltiazem | 40–120 |
| Black (1992)27c | Yes | Yes | 50a | 37 | 56 | 34 | Monotherapy | 12 | Isradipine | 2.5–10 |
| Weir (1992)28 | Yes | No | 35 | 33 | 54.1 | NA | Monotherapy | 2–8 | Nifedipine± | 30–120 |
| Materson (1993A)18d | Yes | Yes | 38 | 37 | NA | 0 | Monotherapy | 4–8 | Diltiazem± | 60–180 |
| Materson (1993B)18d | Yes | Yes | 52 | 53 | NA | 0 | Monotherapy | 4–8 | Diltiazem± | 60–180 |
| Kloner (1996)29 | No | No | 857 | 227 | 55.5 | 35 | Monotherapy | 4 | Amlodipine | 5–10 |
| Wright (2005)20b | Yes | Yes | 4,963a | 2,646 | 66.1 | 54.4 | Add-on therapy Starting with CCB |
52 | Amlodipine | 2.5–10 |
a
Study participants were nonblacks
±
Sustained-release.
b
Not included in pooled analysis.
c
Same rial, two drug groups.
d
Same trial, A = participants <60 years old B = participants ≥60 years old.